Diffuse large B-cell lymphoma trials in France

In France 26 Also abroad 346

26 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in France
A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma
Where
Montpellier Cedex 05, Toulouse Cedex 9
Age
18 years and over
People
10
Run by
Emercell SAS
See details and how to join2024-511843-24-00 · EU 2024-511843-24-00
Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Angers, Argenteuil, Bobigny, Bordeaux, Chambéry, Lille, Lyon, Marseille, Metz-Tessy, Nantes, Nîmes, Paris, Pessac, Poitiers, Quimper, Rennes, Saint-Etienne, Tours, Villejuif
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
Nantes, Paris, Pessac, Pierre-Bénite, Toulouse Cedex 9
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 2/3Taking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Paris Cedex 13, Pierre-Bénite
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Creteil Cedex, Lille, Nantes, Pierre-Bénite, Villejuif Cedex
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Bordeaux, Lyon, Marseille, Nantes, Villejuif
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Avignon, Bayonne, Clermont-Ferrand, Dijon, Dunkirk Cedex 1, Grenoble Cedex 9, La Rochelle, La Roche Sur Yon Cedex 9, Limoges, Metz Cedex 03, Nice Cedex 2, Paris, Rouen Cedex, Saint-Cloud, Strasbourg, Toulon Cedex 9
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 2Taking people
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Where
Grenoble Cedex 9, Montpellier Cedex 5, Pessac, Rennes Cedex 9, Tours Cedex 9
Age
18 years and over
People
130 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Bordeaux, ClermontFerrand, Créteil, Lille, Lyon, Marseille, Montpellier, Paris, Rouen
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 2Not yet taking people in France
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
Where
Créteil, Dijon, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Toulouse, Vandœuvre-lès-Nancy
Age
18 years and over
People
55
Run by
The Lymphoma Academic Research Organisation
See details and how to joinNCT07814001
Phase 2Taking people
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
Where
Amiens, Angers Cedex 9, Bayonne, Clermont-Ferrand, Dijon, Grenoble Cedex 9, Le Chesnay Rocquencourt, Le Mans Cedex 9, Lille Cedex, Limoges, Lomme Cedex, Lyon, Montpellier Cedex 5, Mulhouse, Orleans Cedex 2, Paris, Paris Cedex 12, Pessac, Pierre Benite Cedex, Reims Cedex, Rennes Cedex 9, Rouen, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse, Tours Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
40
Run by
French Innovative Leukemia Organization
See details and how to join2022-501554-11-00 · EU 2022-501554-11-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Bordeaux, Lille, Lyon, Nantes, Strasbourg, Strasbourg Cedex 2, Villejuif
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1Taking people
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Where
Bordeaux, Marseille, Nantes
Age
18 years and over
People
85 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Angers, Bobigny, Nantes, Pessac, Poitiers, Saint-Cloud, Vandœuvre-lès-Nancy
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
No phaseTaking people
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
Where
Montpellier
Age
18 years and over
People
85
Run by
University Hospital, Montpellier
See details and how to joinNCT06352242
Phase 2Taking people
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Where
Bordeaux, Caen, Clermont-Ferrand, Lille, Marseille, Nancy, Paris, Pierre-Bénite, Rennes, Saint-Cloud, Toulouse, Tours
Age
18 years and over
People
60
Run by
The Lymphoma Academic Research Organisation
See details and how to joinNCT06931652
Phase 2Taking people
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Where
Creteil Cedex, Lille Cedex, Marseille, Nantes, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years to 70 years
People
213 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00
Phase 2Taking people
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Where
Créteil, Dijon, La Tronche, Lille, Marseille, Montpellier, Nantes, Paris, Pessac, Rennes, Rouen, Toulouse, Vandœuvre-lès-Nancy
Age
18 years and over
People
65
Run by
The Lymphoma Academic Research Organisation
See details and how to joinNCT06271057
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Creteil Cedex, Villejuif
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
No phaseTaking people
Quality Of Life and Drug Use in Patients With CAR-T Cells
Where
Pierre-Bénite
Age
18 years and over
People
70
Run by
Hospices Civils de Lyon
See details and how to joinNCT04914091
Phase 2/3Taking people
A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated with Lenalidomide and Rituximab
Where
Bordeaux, Caen Cedex 9, Clermont-Ferrand, Lille Cedex, Marseille, Nancy Cedex, Paris Cedex 13, Pierre-Bénite, Rennes, Saint-Cloud, Toulouse Cedex 9, Tours
Age
18 years and over
People
60
Run by
Lysarc
See details and how to join2023-505834-84-00 · EU 2023-505834-84-00
Phase 1Taking people
A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Where
Montpellier
Age
18 years and over
People
10
Run by
Emercell SAS
See details and how to joinNCT07044050
Phase 2Taking people
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Bobigny, Nancy, Nantes, Nice, Paris, Périgueux, Pessac, Saint-Quentin
Age
18 years and over
People
102 worldwide
Run by
ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Nantes, Rouen, Tours
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394
No phaseNot yet taking people in France
Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma
Where
Bordeaux, Le Mans, Nantes, Saint-Nazaire, Strasbourg
Age
18 years and over
People
160
Run by
Weprom
See details and how to joinNCT05298293